SCHEMBL3175503

SCHEMBL3175503

Nc1cccnc1C(=O)Nc1ccc(Cl)cc1

nearest known ligand 0.72

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 10/20 0.72
CYP2C9 P11712 1/20 0.57
ADORA2A P29274 1/20 0.55
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
NPC1 O15118 2/20 0.51
ATR Q13535 1/20 0.51
ALDH1A1 P00352 1/20 0.51
LMNA P02545 1/20 0.51
MAPT P10636 1/20 0.51
HTT P42858 1/20 0.51
RAB9A P51151 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
KDM4E B2RXH2 1/20 0.51
HIF1A Q16665 1/20 0.51
TSHR P16473 1/20 0.51
KDR P35968 1/20 0.50
PRKCI P41743 1/20 0.50
NAMPT P43490 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL938982 0.86 GRM4 (0.69) GRM4CYP2C9CYP3A4ATRALDH1A1
SCHEMBL3901503 0.84 GRM4 (0.60) GRM4NPC1ALDH1A1HTTRAB9A
SCHEMBL14284354 0.83 TLR7 (0.67) GRM4ADORA2ANPC1ALDH1A1LMNA
SCHEMBL13962860 0.82 TRPV1 (0.64) GRM4ADORA2ANPC1ALDH1A1LMNA
SCHEMBL9469239 0.79 NPC1 (0.52) GRM4ADORA2ANPC1ALDH1A1LMNA
SCHEMBL15882338 0.79 GRM4 (0.60) GRM4CYP2C9ATRALDH1A1PRKCI
SCHEMBL12857647 0.79 PRKCI (0.75) GRM4ADORA2ANPC1ALDH1A1LMNA
SCHEMBL18070914 0.78 MAPK1 (0.56) CYP1A2NPC1ATRALDH1A1LMNA
SCHEMBL6595078 0.77 MAPT (0.53) GRM4NPC1ALDH1A1LMNAMAPT
SCHEMBL5291484 0.76 KDM4E (0.58) NPC1ATRALDH1A1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100008866-A1 CIS-CYCLOHEXYL SUBSTITUTED PYRIMIDINONE DERIVATIVES NEUROGEN CORPORATION (US) 2010-01-14 US disclosed
US-20100008866-A1 CIS-CYCLOHEXYL SUBSTITUTED PYRIMIDINONE DERIVATIVES NEUROGEN CORPORATION (US) 2010-01-14 US disclosed
US-20100008866-A1 CIS-CYCLOHEXYL SUBSTITUTED PYRIMIDINONE DERIVATIVES NEUROGEN CORPORATION (US) 2010-01-14 US disclosed
CN-101558069-A Cis-cyclohexyl substituted pyrimidinone derivatives NEUROGEN CORP (US) 2009-10-14 CN disclosed
WO-2009121036-A2 SUBSTITUTED ARYL PYRIMIDINONE DERIVATIVES NEUROGEN CORPORATION (US) 2009-10-01 WO disclosed
WO-2009121036-A2 SUBSTITUTED ARYL PYRIMIDINONE DERIVATIVES NEUROGEN CORPORATION (US) 2009-10-01 WO disclosed
EP-2094704-A2 CIS-CYCLOHEXYL SUBSTITUTED PYRIMIDINONE DERIVATIVES Neurogen Corporation (US) 2009-09-02 EP disclosed
WO-2008066664-A2 CIS-CYCLOHEXYL SUBSTITUTED PYRIMIDINONE DERIVATIVES NEUROGEN CORPORATION (US) 2008-06-05 WO disclosed
WO-2008066664-A2 CIS-CYCLOHEXYL SUBSTITUTED PYRIMIDINONE DERIVATIVES NEUROGEN CORPORATION (US) 2008-06-05 WO disclosed
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives NEUROGEN CORPORATION (US) 2008-04-17 US disclosed
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives NEUROGEN CORPORATION (US) 2008-04-17 US disclosed
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives NEUROGEN CORPORATION (US) 2008-04-17 US disclosed
WO-2008024433-A2 HALOALKYL-SUBSTITUTED PYRIMIDINONE DERIVATIVES NEUROGEN CORPORATION (US) 2008-02-28 WO disclosed
EP-1040108-B1 ORTHO-ANTHRANILAMIDE DERIVATIVES AS ANTI-COAGULANTS SCHERING AG (DE) 2004-02-25 EP disclosed
US-6498185-B1 ENZYME FACTOR XA INHIBITORS BERLEX LABORATORIES, INC. 2002-12-24 US disclosed
US-6380221-B1 FOR THERAPY OF DISEASE-STATES CHARACTERIZED BY THROMBOTIC ACTIVITY BERLEX LABORATORIES, INC. 2002-04-30 US disclosed
US-6140351-A FOR TREATING THROMBOSIS BERLEX LABORATORIES, INC. (US) 2000-10-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives PIGS, GPR174, GPR17 GRM4 877/4885CYP2C9 1572/4885ADORA2A 168/4885
US-20100008866-A1 CIS-CYCLOHEXYL SUBSTITUTED PYRIMIDINONE DERIVATIVES PIGS, GPR174, GPR17 GRM4 553/4885CYP2C9 907/4885ADORA2A 147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.